Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International, randomized, open-label, phase 3 trial of gemcitabine/cisplatin plus PF-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lung cancer

X
Trial Profile

International, randomized, open-label, phase 3 trial of gemcitabine/cisplatin plus PF-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lung cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Agatolimod (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Sep 2022 Results of post-hoc, pooled analysis assessing weight gain and overall survival in patients with non-small cell lung cancer (NSCLC) receiving first-line chemotherapy presented at the 47th European Society for Medical Oncology Congress.
    • 07 Jun 2022 Results of post-hoc, pooled analysis from NCT00254891, NCT00254904, and NCT00596830, examining the relationship between weight gain and overall survival (OS) in patients with NSCLC treated with first-line platinum-based regimens, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 04 Sep 2021 This trial has been completed in Spain (End Date: 25 Aug 2008), according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top